Zobrazeno 1 - 10
of 854
pro vyhledávání: '"HISASHI TANAKA"'
Autor:
Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, Kosuke Hamai, Naoko Matsumoto, Kana Watanabe, Hironori Ashinuma, Eisaku Miyauchi, Koji Sugano, Shinobu Hosokawa, Koji Amano, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemonodo, Kazuhisa Takahashi
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 6, Pp 2618-2628 (2024)
ABSTRACT Background Cancer cachexia complicates advanced non‐small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first‐line systemic therapy. Me
Externí odkaz:
https://doaj.org/article/2bd96d96f73f40fa8b85b8d8ecdb6499
Autor:
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death‐ligand 1 (PD‐L1) expression is an important is
Externí odkaz:
https://doaj.org/article/9abe2da6e7c64c909348f0fdd32c3056
Autor:
Lenka Kasikova, Jana Rakova, Michal Hensler, Tereza Lanickova, Jana Tomankova, Josef Pasulka, Jana Drozenova, Katerina Mojzisova, Anna Fialova, Sarka Vosahlikova, Jan Laco, Ales Ryska, Pavel Dundr, Roman Kocian, Tomas Brtnicky, Petr Skapa, Linda Capkova, Marek Kovar, Jan Prochazka, Ivan Praznovec, Vladimir Koblizek, Alice Taskova, Hisashi Tanaka, Robert Lischke, Fernando Casas Mendez, Jiri Vachtenheim, Viola Heinzelmann-Schwarz, Francis Jacob, Iain A. McNeish, Michal J. Halaska, Lukas Rob, David Cibula, Sandra Orsulic, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that h
Externí odkaz:
https://doaj.org/article/51ecc26da57243349eb37f9d6e8d150d
Autor:
Ou Yamaguchi, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka, Hitomi Nogawa, Hiroaki Satoh, Toshihiro Shiozawa, Kosuke Tsuji, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Thoracic Cancer, Vol 15, Iss 2, Pp 163-171 (2024)
Abstract Background The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first‐line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the out
Externí odkaz:
https://doaj.org/article/69b23a7a31d74e76959dd39356a3e58f
Autor:
Hirotaka Matsumoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Yuki Sato, Daichi Fujimoto, Yoshihiko Taniguchi, Motohiro Tamiya, Yasuhiro Koh, Junya Fukuoka, Hisashi Tanaka, Naoki Furuya, Ryota Shibaki, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Takashi Kijima, Toshihide Yokoyama, Satoru Miura, Akito Hata, Jun Sugisaka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In small-cell lung cancer (SCLC), the tumor immune microenvironment (TIME) could be a promising biomarker for immunotherapy, but objectively evaluating TIME remains challenging. Hence, we aimed to develop a predictive biomarker of immunoth
Externí odkaz:
https://doaj.org/article/6255e060953c4901b89e6055b35b9eff
Autor:
Yoshiyuki Kitaguchi, Rina Hayakawa, Rumi Kawashima, Kenji Matsushita, Hisashi Tanaka, Ryo Kawasaki, Takahiro Fujino, Shinichi Usui, Hiroshi Shimojyo, Tomoyuki Okazaki, Kohji Nishida
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Childhood glaucoma is one of the major causes of blindness in children, however, its diagnosis is of great challenge. The study aimed to demonstrate and evaluate the performance of a deep-learning (DL) model for detecting childhood glaucoma
Externí odkaz:
https://doaj.org/article/9a8a11aebaf847288b66790e5d11978e
Autor:
Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11525-11541 (2023)
Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is uncl
Externí odkaz:
https://doaj.org/article/e841a5a350844541b0287c7aee9ab30b
Autor:
Gloria Cecilia Galvan, Nadine A. Friedrich, Sanjay Das, James P. Daniels, Sara Pollan, Shweta Dambal, Ryusuke Suzuki, Sergio E. Sanders, Sungyong You, Hisashi Tanaka, Yeon-Joo Lee, Wei Yuan, Johann S. de Bono, Irina Vasilevskaya, Karen E. Knudsen, Michael R. Freeman, Stephen J. Freedland
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionWe previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in PCs. We observed that restoring
Externí odkaz:
https://doaj.org/article/ec60d6dd2eac4bd18a56190427b615e9
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Autor:
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 2, Pp 168-176 (2023)
Abstract Background The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non–small cell lung cancer; however, it is unclear whether the same is applicable for small cell
Externí odkaz:
https://doaj.org/article/8194827c78724e359bab2959b6fa2bc1